Integrated One-stop Drug Discovery Platform Accelerating Project with High Efficiency
Infectious diseases still remain to be one of the biggest global public health concerns. Virus infection and antibiotic resistance are the serious, worldwide threat to public health.
HitGen team have expertise in anti-infectives discovery and development, and can provide integrated anti-infectives discovery programs by using cutting edge technologies such as protein degradation, siRNA and covalent DEL screening.
Services for infectious diseases drug discovery and development:
Target proposal
Recombinant target protein production
Biochemical assays dvelopment
Structure based design
Screening and lead identification
in vitro bacterial efficacy (such as MIC50/MIC90/ MBC/ PAE)
Cytopathic effect (CPE) screen
in vivo bacterial or fungal efficacy
Drug metabolism and pharmacokinetics (DMPK)
Safety
IND submission
HitGen Inc.
Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China
Tel : +86-28-8519-7385
HitGen Pharmaceuticals Inc.(US Subsidiary)
Tel : +1-(508)-840-9646
Vernalis (R&D) Limited (UK Subsidiary)
Granta Park,Great Abington
Cambridge,CB21 6GB
United Kingdom
Tel : +44(0)1223-895555
川公网安备 51012202000492号
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information
